Regulatory approval

Published by the Health Service Executive.

The Republic of Ireland's Health Service Executive (HSE) has approved trametinib in combination with dabrafenib for reimbursement as a treatment option for the adjuvant treatment of adult patients with stage III melanoma with a BRAF V600 mutation, following complete resection.

This is written in the approval document as:

Adjuvant treatment of adult patients with Stage III melanoma with a BRAF V600 mutation, following complete resection.

Citation

Trametinib and Dabrafenib Therapy, 2021, version number 4, NCCP National SACT Regimen, NCCP, viewed on 18/01/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/melanoma/dabrafenib%20and%20trametinib%20therapy.pdf

View API

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Type Biomarker(s) Cancer type Therapy(ies)
Sensitivity (+) BRAF p.V600E Melanoma Dabrafenib, Trametinib
Sensitivity (+) BRAF p.V600K Melanoma Dabrafenib, Trametinib